{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-000661","form_type":"8-K","ticker":"PAHC","cik":"0001069899","company_name":"PHIBRO ANIMAL HEALTH CORP","filed_at":"2025-02-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:02.860412+00:00","generated_at":"2026-05-27T02:20:26.825461+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Phibro Q2 net sales up 24% to $309M; adjusted EPS $0.54 (+64% YoY); raises FY25 guidance","bullets":["Net sales $309.3M (+24% YoY); Animal Health up 33% on Zoetis MFA acquisition added $36.7M.","Adjusted EBITDA $48.2M (+64% YoY); gross margin up 140 bps to 32.9%.","Net income $3.2M vs $1.3M prior year; adjusted net income $21.9M (+$8.5M).","Updated FY2025 guidance: net sales $1.25-1.30B, adjusted EBITDA $172-180M (58% growth midpoint).","Gross leverage 3.1x; total debt $760.3M; cash $67.1M; free cash flow $15.3M trailing 12M."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-000661","json":"https://secwatch.observer/filing/0001558370-25-000661.json","markdown":"https://secwatch.observer/filing/0001558370-25-000661.md","text":"https://secwatch.observer/filing/0001558370-25-000661.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1069899/000155837025000661/0001558370-25-000661-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1069899/000155837025000661/pahc-20250205x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T02:20:26.825461+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}